Author

I. Collins

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biophysics· 1 Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

A. A. Antolin· 1 shared A. E. Campbell· 1 shared B. Al-Lazikani· 1 shared C. E. Eyers· 1 shared H. D. Thomas· 1 shared H. Sellier· 1 shared J. A. Butterworth· 1 shared J. Coxhead· 1 shared

Activity by Year

2019-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 22 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

A. A. Antolin

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Regulation of CHK1 inhibitor resistance by a c-Rel and USP1 dependent pathway

J. E. Hunter, A. E. Campbell, N. L. Hannaway, S. Kerridge, S. Luli, J. A. Butterworth, H. Sellier, R. Mukherjee, H. D. Thomas, P. J. Brownridge, J. Coxhead, L. Taylor, P. Leary, M. S. R. Hasoon, I. Collins, , N. D. Perkins

The paper identifies a c-Rel and USP1 dependent pathway that regulates CHK1 inhibitor resistance in lymphoma cells.

bioRxiv · May 26, 2021Cancer Biology

Evolution of kinase polypharmacology across HSP90 drug discovery

A. A. Antolin, P. A. Clarke, I. Collins, P. Workman, B. Al-Lazikani

This study systematically characterizes the kinase cross-pharmacology of HSP90 inhibitors and shows that polypharmacology evolved during drug optimization.

bioRxiv · Sep 9, 2020Pharmacology & Toxicology

Fragment-based screening identifies molecules targeting the substrate-binding ankyrin repeat domains of tankyrase

K. Pollock, M. Liu, M. Zaleska, M. Pfuhl, I. Collins, S. Guettler

This study identifies fragment molecules targeting tankyrase's substrate-binding ankyrin repeat domains through biophysical assays, offering potential new therapeutic approaches for cancer.

bioRxiv · Mar 4, 2019Biophysics